Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

Phase 2 Study of Aspirin Plus Exemestane Comparing With Exemestane Alone in the Adjuvant Treatment of Postmenopausal Breast Cancer

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01431053

Enrollment

160

Registered

2011-09-09

Start date

2011-07-31

Completion date

2014-07-31

Last updated

2013-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Keywords

exemestane, aspirin, quality of life

Brief summary

This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.

Interventions

DRUGaspirin

Aspirin 50mg po daily

DRUGExemestane

Exemestane 25mg po daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

50 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Breast cancer after surgery postmenopausal

Exclusion criteria

* contraindication of aspirin

Design outcomes

Primary

Measure	Time frame
Quality of Life	4 years

Countries

China

Contacts

Primary ContactPeng Yuan, M.D.

yuanpeng01@hotmail.com86-135 0127 0834

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026